Trevena (NASDAQ: TRVN) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Trevena to related companies based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, dividends and institutional ownership.
Earnings & Valuation
This table compares Trevena and its rivals revenue, earnings per share and valuation.
Trevena’s rivals have higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings for Trevena and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
Trevena currently has a consensus target price of $7.94, suggesting a potential upside of 367.32%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.52%. Given Trevena’s stronger consensus rating and higher probable upside, research analysts clearly believe Trevena is more favorable than its rivals.
Risk and Volatility
Trevena has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, Trevena’s rivals have a beta of 2.41, indicating that their average share price is 141% more volatile than the S&P 500.
This table compares Trevena and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional & Insider Ownership
56.9% of Trevena shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.6% of Trevena shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Trevena rivals beat Trevena on 8 of the 13 factors compared.
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.